| An update on the physiological and therapeutic relevance of GPCR oligomers B Farran Pharmacological research 117, 303-327, 2017 | 113 | 2017 |
| Folate-conjugated nanovehicles: Strategies for cancer therapy B Farran, RC Montenegro, P Kasa, E Pavitra, YS Huh, YK Han, MA Kamal, ... Materials Science and Engineering: C 107, 110341, 2020 | 75 | 2020 |
| Reactive oxygen species (ROS): Critical roles in breast tumor microenvironment RR Malla, N Surepalli, B Farran, SV Malhotra, GP Nagaraju Critical Reviews in Oncology/Hematology 160, 103285, 2021 | 45 | 2021 |
| Nanoparticles guided drug delivery and imaging in gastric cancer GP Nagaraju, G Srivani, B Dariya, G Chalikonda, B Farran, SK Behera, ... Seminars in Cancer Biology 69, 69-76, 2021 | 44 | 2021 |
| Horizons of nanotechnology applications in female specific cancers B Rajitha, RR Malla, R Vadde, P Kasa, GLV Prasad, B Farran, S Kumari, ... Seminars in cancer biology 69, 376-390, 2021 | 41 | 2021 |
| Molecular docking studies of angiogenesis target protein HIF-1α and genistein in breast cancer V Mukund, MS Saddala, B Farran, M Mannavarapu, A Alam, GP Nagaraju Gene 701, 169-172, 2019 | 40 | 2019 |
| The dynamic interactions between the stroma, pancreatic stellate cells and pancreatic tumor development: Novel therapeutic targets B Farran, GP Nagaraju Cytokine & growth factor reviews 48, 11-23, 2019 | 37 | 2019 |
| Folate-targeted immunotherapies: Passive and active strategies for cancer B Farran, E Pavitra, P Kasa, S Peela, GSR Raju, GP Nagaraju Cytokine & growth factor reviews 45, 45-52, 2019 | 37 | 2019 |
| Gastric cancer management: kinases as a target therapy B Farran, S Müller, RC Montenegro Clinical and Experimental Pharmacology and Physiology 44 (6), 613-622, 2017 | 36 | 2017 |
| Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib RC Montenegro, A Howarth, A Ceroni, V Fedele, B Farran, FP Mesquita, ... Oncotarget 11 (5), 535, 2020 | 31 | 2020 |
| Nanoparticles mediated tumor microenvironment modulation: current advances and applications GSR Raju, E Pavitra, GL Varaprasad, SS Bandaru, GP Nagaraju, ... Journal of Nanobiotechnology 20 (1), 274, 2022 | 29 | 2022 |
| Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles BVKS Lakkakula, B Farran, S Lakkakula, S Peela, NS Yarla, ... Seminars in cancer biology 56, 149-167, 2019 | 28 | 2019 |
| A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer B Farran, G Dyson, D Craig, A Dombkowski, JL Beebe-Dimmer, IJ Powell, ... Carcinogenesis 39 (4), 556-561, 2018 | 28 | 2018 |
| Convalescent plasma transfusion a promising therapy for coronavirus diseases 2019 (COVID-19): current updates HK Verma, B Farran, LVKS Bhaskar Antibody Therapeutics 3 (2), 115-125, 2020 | 23 | 2020 |
| Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer GP Nagaraju, B Farran, M Farren, G Chalikonda, C Wu, GB Lesinski, ... Cancer 126 (14), 3360-3371, 2020 | 21 | 2020 |
| Mitochondrial-targeted nanoparticles: Delivery and therapeutic agents in cancer C Ganji, V Muppala, M Khan, GP Nagaraju, B Farran Drug Discovery Today 28 (3), 103469, 2023 | 16 | 2023 |
| Aquaporins in female specific cancers P Kasa, B Farran, GLV Prasad, GP Nagaraju Gene 700, 60-64, 2019 | 13 | 2019 |
| Computational analysis of nuclear factor-κB and resveratrol in colorectal cancer B Dariya, SK Behera, G Srivani, B Farran, A Alam, GP Nagaraju Journal of Biomolecular Structure and Dynamics 39 (8), 2914-2922, 2021 | 10 | 2021 |
| The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer G Dyson, B Farran, S Bolton, DB Craig, A Dombkowski, JL Beebe-Dimmer, ... American Journal of Cancer Research 8 (10), 2088, 2018 | 10 | 2018 |
| Understanding the molecular mechanisms that regulate pancreatic cancer stem cell formation, stemness and chemoresistance: a brief overview GP Nagaraju, B Farran, T Luong, BF El-Rayes Seminars in Cancer Biology 88, 67-80, 2023 | 9 | 2023 |
